 CAMBRIDGE, Mass. MONTREAL, Quebec--BUSINESS WIRE--Repare Therapeutics Inc. Repare or the Company Nasdaq: RPTX, a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its President and Chief Executive Officer Lloyd Segal, Executive Vice President, Chief Scientific Officer Michael Zinda, Executive Vice President, Discovery Cameron Black, and Executi 